Nuvation Bio Inc. (NYSE:NUVB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Nuvation Bio Inc. (NYSE:NUVB) have been given an average rating of “Moderate Buy” by the eleven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.6667.

A number of equities research analysts recently commented on NUVB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a report on Thursday, January 22nd. UBS Group assumed coverage on Nuvation Bio in a research report on Wednesday, January 7th. They set a “neutral” rating and a $10.00 price target on the stock. Truist Financial set a $13.00 price target on Nuvation Bio in a research note on Tuesday, January 27th. HC Wainwright lowered their price objective on Nuvation Bio from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Finally, B. Riley Financial assumed coverage on shares of Nuvation Bio in a report on Wednesday, November 19th. They set a “buy” rating and a $12.00 price objective on the stock.

Nuvation Bio Price Performance

NUVB opened at $5.47 on Tuesday. Nuvation Bio has a fifty-two week low of $1.54 and a fifty-two week high of $9.75. The firm has a 50-day moving average of $6.98 and a 200 day moving average of $5.41. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.39 and a current ratio of 8.48. The firm has a market cap of $1.87 billion, a P/E ratio of -8.54 and a beta of 1.52.

Insider Buying and Selling

In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the sale, the insider owned 18,000 shares of the company’s stock, valued at $140,760. The trade was a 89.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 29.93% of the company’s stock.

Hedge Funds Weigh In On Nuvation Bio

Several hedge funds have recently made changes to their positions in the stock. Los Angeles Capital Management LLC purchased a new stake in shares of Nuvation Bio in the 2nd quarter valued at about $207,000. Tema Etfs LLC purchased a new stake in Nuvation Bio in the second quarter valued at approximately $272,000. Brighton Jones LLC bought a new stake in Nuvation Bio during the second quarter valued at approximately $120,000. Ashton Thomas Private Wealth LLC bought a new stake in Nuvation Bio during the second quarter valued at approximately $131,000. Finally, Geode Capital Management LLC grew its stake in Nuvation Bio by 16.8% in the 2nd quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock worth $11,691,000 after buying an additional 864,194 shares in the last quarter. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.